OBJECTIVE: To examine predictors of opioid abstinence in buprenorphine/naloxone (Bup/Nal)-assisted psychosocial treatment for opioid-dependent youth. METHOD: Secondary analyses were performed of data from 152 youth (15-21 years old) randomly assigned to 12 weeks of extended Bup/Nal therapy or up to 2 weeks of Bup/Nal detoxification with weekly individual and group drug counseling. Logistic regression models were constructed to identify baseline and during-treatment predictors of opioid-positive urine (OPU) at week 12. Predictors were selected based on significance or trend toward significance (i.e., p < .1), and backward stepwise selection was used, controlling for treatment group, to produce final independent predictors at p ≤ .05. RESULTS: Youth presenting to treatment with previous 30-day injection drug use and more active medical/psychiatric problems were less likely to have a week-12 OPU. Those with early treatment opioid abstinence (i.e., weeks 1 and 2) and those who received additional nonstudy treatments during the study were less likely to have a week-12 OPU and those not completing 12 weeks of treatment were more likely to have an OPU. CONCLUSIONS:Youth with advanced illness (i.e., reporting injection drug use and additional health problems) and those receiving ancillary treatments to augment study treatment were more likely to have lower opioid use. Treatment success in the first 2 weeks and completion of 12 weeks of treatment were associated with lower rates of OPU. These findings suggest that youth with advanced illness respond well to Bup/Nal treatment and identify options for tailoring treatment for opioid-dependent youth presenting at community-based settings. CLINICAL TRIAL REGISTRATION INFORMATION: Buprenorphine/Naloxone-Facilitated Rehabilitation for Opioid Dependent Adolescents; http://www.clinicaltrials.gov; NCT00078130.
RCT Entities:
OBJECTIVE: To examine predictors of opioid abstinence in buprenorphine/naloxone (Bup/Nal)-assisted psychosocial treatment for opioid-dependent youth. METHOD: Secondary analyses were performed of data from 152 youth (15-21 years old) randomly assigned to 12 weeks of extended Bup/Nal therapy or up to 2 weeks of Bup/Nal detoxification with weekly individual and group drug counseling. Logistic regression models were constructed to identify baseline and during-treatment predictors of opioid-positive urine (OPU) at week 12. Predictors were selected based on significance or trend toward significance (i.e., p < .1), and backward stepwise selection was used, controlling for treatment group, to produce final independent predictors at p ≤ .05. RESULTS: Youth presenting to treatment with previous 30-day injection drug use and more active medical/psychiatric problems were less likely to have a week-12 OPU. Those with early treatment opioid abstinence (i.e., weeks 1 and 2) and those who received additional nonstudy treatments during the study were less likely to have a week-12 OPU and those not completing 12 weeks of treatment were more likely to have an OPU. CONCLUSIONS: Youth with advanced illness (i.e., reporting injection drug use and additional health problems) and those receiving ancillary treatments to augment study treatment were more likely to have lower opioid use. Treatment success in the first 2 weeks and completion of 12 weeks of treatment were associated with lower rates of OPU. These findings suggest that youth with advanced illness respond well to Bup/Nal treatment and identify options for tailoring treatment for opioid-dependent youth presenting at community-based settings. CLINICAL TRIAL REGISTRATION INFORMATION: Buprenorphine/Naloxone-Facilitated Rehabilitation for Opioid Dependent Adolescents; http://www.clinicaltrials.gov; NCT00078130.
Authors: David A Fiellin; Michael V Pantalon; Marek C Chawarski; Brent A Moore; Lynn E Sullivan; Patrick G O'Connor; Richard S Schottenfeld Journal: N Engl J Med Date: 2006-07-27 Impact factor: 91.245
Authors: Lisa A Marsch; Mary Ann Chutuape Stephens; Timothy Mudric; Eric C Strain; George E Bigelow; Rolley E Johnson Journal: Exp Clin Psychopharmacol Date: 2005-11 Impact factor: 3.157
Authors: Elizabeth C Katz; Robert P Schwartz; Stuart King; David A Highfield; Kevin E O'Grady; Timothy Billings; Devang Gandhi; Eric Weintraub; David Glovinsky; Wardell Barksdale; Barry S Brown Journal: Am J Drug Alcohol Abuse Date: 2009 Impact factor: 3.829
Authors: Katherine A McDermott; Margaret L Griffin; Hilary S Connery; E Yvette Hilario; David A Fiellin; Garrett M Fitzmaurice; Roger D Weiss Journal: J Clin Psychiatry Date: 2015-02 Impact factor: 4.384
Authors: Diane Warden; Geetha A Subramaniam; Thomas Carmody; George E Woody; Abu Minhajuddin; Sabrina A Poole; Jennifer Potter; Marc Fishman; Michael Bogenschutz; Ashwin Patkar; Madhukar H Trivedi Journal: Addict Behav Date: 2012-05-08 Impact factor: 3.913
Authors: Adam Viera; Daniel J Bromberg; Shannon Whittaker; Bryan M Refsland; Milena Stanojlović; Kate Nyhan; Frederick L Altice Journal: Epidemiol Rev Date: 2020-01-31 Impact factor: 6.222
Authors: Kevin P Hill; Heather E Bennett; Margaret L Griffin; Hilary S Connery; Garrett M Fitzmaurice; Geetha Subramaniam; George E Woody; Roger D Weiss Journal: Drug Alcohol Depend Date: 2013-03-22 Impact factor: 4.492
Authors: Erin A McClure; Susan C Sonne; Theresa Winhusen; Kathleen M Carroll; Udi E Ghitza; Aimee L McRae-Clark; Abigail G Matthews; Gaurav Sharma; Paul Van Veldhuisen; Ryan G Vandrey; Frances R Levin; Roger D Weiss; Robert Lindblad; Colleen Allen; Larissa J Mooney; Louise Haynes; Gregory S Brigham; Steve Sparenborg; Albert L Hasson; Kevin M Gray Journal: Contemp Clin Trials Date: 2014-08-30 Impact factor: 2.226